Study of Atezolizumab and WT1DC Vaccine with PlatinumPemetrexed Chemotherapy for Treating Epithelioid Malignant Pleural Mesothelioma

What this Trial Is About

Researchers are evaluating the combination of atezolizumab, a PD-L1 inhibitor, and a WT1-targeted dendritic cell vaccine with standard platinumpemetrexed chemotherapy as a first-line treatment for patients with epithelioid malignant pleural mesothelioma MPM. This aggressive cancer, often linked to asbestos exposure, has a poor prognosis with median survival of 9-16 months. The trial aims to show that this new chemo-immunotherapy approach is safe, feasible, and can trigger immune responses against mesothelioma. Participants will receive four cycles of chemotherapy every three weeks, each combined with atezolizumab infusions on day 0 and WT1DC vaccines on days 0 and 14 of each cycle. After completing this treatment phase, optional additional doses of atezolizumab and WT1DC vaccines may be given every four weeks if the patient agrees and vaccine supply permits. Following treatment, patients enter a follow-up period lasting up to 90 days after the last vaccine or atezolizumab dose or up to 24 months after diagnosis, whichever is longer. During the study, patients will undergo regular assessments for safety, including monitoring of adverse events possibly related to the treatments, and evaluation of treatment completion. Researchers will also measure clinical responses such as tumor control and survival over an average of two years. Immune responses specific to WT1 will be assessed after the fourth vaccine and at later timepoints if disease control is sustained. The study involves a total participation duration covering treatment and extended follow-up for safety and effectiveness.

Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma